Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 7/20 | 0.60 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.54 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.53 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.53 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 4/20 | 0.52 |
| ▸ | CTSL | P07711 | 3/20 | 0.52 |
| ▸ | CTSB | P07858 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.50 |
| ▸ | PLG | P00747 | 1/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4561159 | 1.00 | CTSK (0.60) | CTSKCAPN1PSMB8PSMB9PSMB5 | |
| SCHEMBL29577075 | 1.00 | CTSK (0.60) | CTSKCAPN1PSMB8PSMB9PSMB5 | |
| SCHEMBL10608051 | 1.00 | CTSK (0.60) | CTSKCAPN1PSMB8PSMB9PSMB5 | |
| SCHEMBL4561049 | 0.91 | CTSK (0.59) | CTSKCAPN1PSMB8PSMB9PSMB5 | |
| SCHEMBL8557434 | 0.91 | CTSK (0.59) | CTSKCAPN1PSMB8PSMB9PSMB5 | |
| SCHEMBL4560701 | 0.91 | CTSK (0.59) | CTSKCAPN1PSMB8PSMB9PSMB5 | |
| SCHEMBL1436898 | 0.90 | CAPN1 (0.62) | CTSKCAPN1CTSSCTSLCTSB | |
| SCHEMBL9830575 | 0.90 | CAPN1 (0.62) | CTSKCAPN1CTSSCTSLCTSB | |
| SCHEMBL4559069 | 0.89 | CTSK (0.57) | CTSKCAPN1PSMB8PSMB9PSMB5 | |
| SCHEMBL7155003 | 0.88 | MME (0.59) | CTSKCAPN1PSMB8PSMB9PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261372-A1 | Derivatives of glycinergic r(+)-2-amino-3-hydroxypropanoic acid | ORAPHARMA, INC. | 2005-11-24 | — | — | US | claimed |
| EP-1529030-A2 | DERIVATIVES OF GLYCINERGIC R(+)-2-AMINO-3-HYDROXYPROPANOIC ACID | Prestwick Pharmaceuticals, Inc. (US) | 2005-05-11 | — | — | EP | claimed |
| WO-2004016580-A2 | DERIVATIVES OF GLYCINERGIC R(+)-2-AMINO-3-HYDROXYPROPANOIC ACID | PRESTWICK PHARMACEUTICALS, INC. (US) | 2004-02-26 | — | — | WO | claimed |
| US-7488755-B2 | Derivatives of glycinergic R(+)-2-amino-3-hydroxypropanoic acid | PRESTWICK PHARMACEUTICALS, INC. (US) | 2009-02-10 | — | — | US | disclosed |
| US-20050261372-A1 | Derivatives of glycinergic r(+)-2-amino-3-hydroxypropanoic acid | ORAPHARMA, INC. | 2005-11-24 | — | — | US | disclosed |
| EP-1529030-A2 | DERIVATIVES OF GLYCINERGIC R(+)-2-AMINO-3-HYDROXYPROPANOIC ACID | Prestwick Pharmaceuticals, Inc. (US) | 2005-05-11 | — | — | EP | disclosed |
| WO-2004016580-A2 | DERIVATIVES OF GLYCINERGIC R(+)-2-AMINO-3-HYDROXYPROPANOIC ACID | PRESTWICK PHARMACEUTICALS, INC. (US) | 2004-02-26 | — | — | WO | disclosed |
| EP-0094815-B1 | OLIGOPEPTIDE PRODRUGS | SMITHKLINE BECKMAN CORPORATION (US) | 1989-01-11 | — | — | EP | disclosed |
| EP-0094815-A2 | Oligopeptide prodrugs | SMITHKLINE BECKMAN CORPORATION (US) | 1983-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261372-A1 | Derivatives of glycinergic r(+)-2-amino-3-hydroxypropanoic acid | GLRA3, GLRA1, GLRA2 | CTSK 4036/4885CAPN1 1697/4885PSMB8 2619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.